Ranbaxy JV launches antibiotic and anti fungal in Japan

New Delhi, July 17 (UNI) Ranbaxy Laboratories today announced that Nihon Pharmaceutical Industry (NPI), a joint venture between the company and Nippon Chemiphar (NC), has launched Clarithromycin and Terbinafine tablets in Japan.

The products will be sold under the Ranbaxy/Nihon Pharmaceutical Industry Ltd label and will be marketed and actively promoted to doctors in hospitals as well as in clinics jointly by the field forces of NC and NPI.

''It is our earnest intention to leverage the advantage of an early entry in the progressive opening up of the generic pharma market of Japan. We intend to rapidly introduce an array of generic therapies from our global portfolio,'' Ranbaxy CMD Malvinder Mohan Singh said.

The company entered the Japanese market in 2002 through a strategic alliance with a mid-sized research pharmaceutical company Nippon Chemiphar (NC) of Japan. In November 2005 the company increased its equity stake in NPI to become a 50:50 joint venture between Ranbaxy and Nippon Chemiphar.

Clarithromycin 50mg, 200mg is an antibiotic and Terbinafine 125 mg an anti fungal with a market size of around 400 million dollars and 300 million dollars respectively, in Japan.

UNI CS PV PM1627